SG10202011470UA - Compositions and methods for treating negative symptoms in non-schizophrenic patients - Google Patents
Compositions and methods for treating negative symptoms in non-schizophrenic patientsInfo
- Publication number
- SG10202011470UA SG10202011470UA SG10202011470UA SG10202011470UA SG10202011470UA SG 10202011470U A SG10202011470U A SG 10202011470UA SG 10202011470U A SG10202011470U A SG 10202011470UA SG 10202011470U A SG10202011470U A SG 10202011470UA SG 10202011470U A SG10202011470U A SG 10202011470UA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- negative symptoms
- schizophrenic patients
- treating negative
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 230000000698 schizophrenic effect Effects 0.000 title 1
- 208000024891 symptom Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341590P | 2016-05-25 | 2016-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202011470UA true SG10202011470UA (en) | 2021-01-28 |
Family
ID=58794265
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202011470UA SG10202011470UA (en) | 2016-05-25 | 2017-05-23 | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
| SG11201810358YA SG11201810358YA (en) | 2016-05-25 | 2017-05-23 | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810358YA SG11201810358YA (en) | 2016-05-25 | 2017-05-23 | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190216793A1 (https=) |
| EP (1) | EP3463356A1 (https=) |
| JP (3) | JP2019516756A (https=) |
| KR (2) | KR20240005110A (https=) |
| CN (3) | CN113908156A (https=) |
| PH (1) | PH12018502445A1 (https=) |
| SG (2) | SG10202011470UA (https=) |
| TW (2) | TWI820001B (https=) |
| WO (1) | WO2017205393A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3227273T3 (pl) | 2014-12-02 | 2022-05-30 | Minerva Neurosciences, Inc. | Kompozycje zawierające 2-((1-(2-(4-fluorofenylo)-2-oksoetylo)piperydyn-4-ylo)metylo)izoindolin-1-on do leczenia schizofrenii |
| IL319156A (en) | 2017-06-21 | 2025-04-01 | Minerva Neurosciences Inc | Controlled-release oral dosage forms are resistant to gastric acid. |
| EP3840835A1 (en) * | 2018-08-21 | 2021-06-30 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
| TWI879755B (zh) * | 2020-02-20 | 2025-04-11 | 日商田邊三菱製藥股份有限公司 | 魯哌啶酮用於治療負性症狀及疾病、增加神經可塑性及促進神經保護的用途 |
| KR102360137B1 (ko) * | 2020-03-25 | 2022-02-08 | 주식회사 케이티앤지 | 카트리지 및 이를 포함하는 에어로졸 생성 장치 |
| US11957675B2 (en) * | 2021-02-09 | 2024-04-16 | Xenon Pharmaceuticals Inc. | Methods and uses for treating anhedonia |
| WO2024138073A1 (en) * | 2022-12-21 | 2024-06-27 | Woebot Labs, Inc. | Administering a digital therapeutic using a device interface to treat anxiety or depression |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7166617B2 (en) * | 2000-02-29 | 2007-01-23 | Mitsubishi Pharma Corporation | Cyclic amide derivatives |
| TW200616608A (en) * | 2004-07-09 | 2006-06-01 | Forest Laboratories | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
| US20090088449A1 (en) * | 2006-02-07 | 2009-04-02 | Mitsubishi Tanabe Pharma Corporation | 4-acylaminopyridine derivative mediated neurogenesis |
| KR20080089279A (ko) * | 2007-03-30 | 2008-10-06 | 미쓰비시 타나베 파마 코퍼레이션 | 우울증의 예방 및/또는 치료제 |
| US8937900B2 (en) * | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
| RS64819B1 (sr) * | 2010-07-20 | 2023-12-29 | Minerva Neurosciences Inc | Metode upotrebe derivata cikličnih amida za lečenje šizofrenije i njenih simptoma |
| TWI520949B (zh) * | 2010-07-20 | 2016-02-11 | 錫蘭尼克藥物有限公司 | 使用環醯胺衍生物治療σ受體介導之病症的方法 |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| EP3144308B1 (en) * | 2014-05-16 | 2020-06-24 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| PL3227273T3 (pl) * | 2014-12-02 | 2022-05-30 | Minerva Neurosciences, Inc. | Kompozycje zawierające 2-((1-(2-(4-fluorofenylo)-2-oksoetylo)piperydyn-4-ylo)metylo)izoindolin-1-on do leczenia schizofrenii |
-
2017
- 2017-05-23 TW TW106117023A patent/TWI820001B/zh active
- 2017-05-23 KR KR1020237043697A patent/KR20240005110A/ko not_active Ceased
- 2017-05-23 TW TW112118953A patent/TWI851224B/zh active
- 2017-05-23 CN CN202111014298.8A patent/CN113908156A/zh active Pending
- 2017-05-23 EP EP17726525.3A patent/EP3463356A1/en not_active Withdrawn
- 2017-05-23 US US16/302,722 patent/US20190216793A1/en not_active Abandoned
- 2017-05-23 WO PCT/US2017/034030 patent/WO2017205393A1/en not_active Ceased
- 2017-05-23 JP JP2018561528A patent/JP2019516756A/ja active Pending
- 2017-05-23 SG SG10202011470UA patent/SG10202011470UA/en unknown
- 2017-05-23 CN CN201780045461.2A patent/CN109689055A/zh active Pending
- 2017-05-23 KR KR1020187036656A patent/KR20190013846A/ko not_active Ceased
- 2017-05-23 SG SG11201810358YA patent/SG11201810358YA/en unknown
- 2017-05-23 CN CN202111014262.XA patent/CN113694065A/zh active Pending
-
2018
- 2018-11-20 PH PH12018502445A patent/PH12018502445A1/en unknown
-
2022
- 2022-05-26 US US17/825,783 patent/US20230190726A1/en not_active Abandoned
- 2022-10-04 JP JP2022160201A patent/JP2022188185A/ja active Pending
-
2024
- 2024-10-02 JP JP2024173054A patent/JP2025000921A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| TW202335672A (zh) | 2023-09-16 |
| US20230190726A1 (en) | 2023-06-22 |
| PH12018502445A1 (en) | 2019-09-09 |
| JP2025000921A (ja) | 2025-01-07 |
| CN109689055A (zh) | 2019-04-26 |
| CN113694065A (zh) | 2021-11-26 |
| CN113908156A (zh) | 2022-01-11 |
| EP3463356A1 (en) | 2019-04-10 |
| JP2019516756A (ja) | 2019-06-20 |
| TWI820001B (zh) | 2023-11-01 |
| US20190216793A1 (en) | 2019-07-18 |
| SG11201810358YA (en) | 2018-12-28 |
| JP2022188185A (ja) | 2022-12-20 |
| KR20190013846A (ko) | 2019-02-11 |
| TWI851224B (zh) | 2024-08-01 |
| KR20240005110A (ko) | 2024-01-11 |
| WO2017205393A1 (en) | 2017-11-30 |
| TW201808288A (zh) | 2018-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252943A0 (en) | Sunitinib formulations and methods of using them for the treatment of eye diseases | |
| SG10202011470UA (en) | Compositions and methods for treating negative symptoms in non-schizophrenic patients | |
| PT3240554T (pt) | Blautia stercosis e wexlerae para uso no tratamento de doenças inflamatórias e autoimunes | |
| SG11201703203RA (en) | Methods and compositions for dosing in adoptive cell therapy | |
| EP3212207A4 (en) | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders | |
| EP3212289A4 (en) | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders | |
| AP2017009674A0 (en) | Methods and compositions for treating ulcers | |
| IL251371A0 (en) | Cortexolone 17alpha-benzoate for use in the treatment of tumors | |
| EP3212003A4 (en) | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders | |
| IL271256A (en) | Preparations and methods for the treatment of teopathy | |
| GB201621394D0 (en) | Improvements in and relating to waste treatment | |
| ZA201705400B (en) | Compositions containing arsenic and their use in methods of treatment | |
| SMT202200151T1 (it) | Composizioni e metodi per l’uso nel trattamento di omocistinuria. | |
| IL246855A0 (en) | Materials for use in the treatment of retinitis | |
| IL246587A0 (en) | Preparations for use in the treatment of allergic conditions | |
| SMT202200221T1 (it) | Medicinale per l'uso nel trattamento della gotta | |
| GB201614318D0 (en) | Methods and compositions used in treating inflammatory and autoimmune diseases | |
| PL3212280T3 (pl) | Dopasowanie szumu usznego u pacjentów z implantem ślimakowym (CI) i implantem słuchowym pnia mózgu (ABI) | |
| GB2510477B (en) | Formulations for use in the treatment of chronic fatigue and associated conditions, etc | |
| ZA201801788B (en) | Lysobactin for use in the treatment of bovine mastitis | |
| ZA201408464B (en) | Composition for the use in treatment of asthma |